Impact of hypoalbuminemia on the prognosis of relapsed/refractory B‐cell lymphoma treated with axicabtagene ciloleucel

Abstract

Introduction Hypoalbuminemia is a known adverse prognostic factor in lymphomas. Yet, it is unknown if axicabtagene ciloleucel (axi‐cel) overcomes the adverse prognostic impact of hypoalbuminemia in relapsed/refractory large B‐cell lymphoma. Methods We conducted a retrospective analysis across three Mayo Clinic centers to assess the relationship of hypoalbuminemia (defined as a serum albumin (SA) levels ≤ 3.5 g/dL) on outcomes of patients treated with axi‐cel. Results This analysis included 81 patients. Two patients had no available SA levels preceding axi‐cel infusion. Eighteen patients (22.8%) had hypoalbuminemia with a median SA of 3.3 g/dL. Patients with normal SA had a statistically higher ORR than those without hypoalbuminemia (P = .018). There was no difference in 1‐year PFS and OS between the group with hypoalbuminemia and the group with normal SA levels (48% vs 49%, P = .81) and (74% vs 73%, P = .97), respectively. There was no difference in the severity or median duration of cytokine release syndrome or neurotoxicity between the two groups. Conclusion Notwithstanding the limitations related to the relatively small sample size, axi‐cel therapy appears to overcome the adverse effect of hypoalbuminemia on OS and PFS. Large multicenter clinical studies are certainly needed to validate these findings.

Serum α-hydroxybutyrate dehydrogenase as a biomarker for predicting survival outcomes in patients with UTUC after radical nephroureterectomy

“…In the present study, albumin was not an independent risk factor for CSS. Hypoalbuminemia was previously proven to be strongly associated with cancer patients’ worsened OS and PFS, but the clinical practice of the single factor was limited because it could be easily affected by liver function, fluid volume and systemic inflammation [ 21 – 23 ]. This might be the reason for the results in our study.…”

Diagnostic Value of OPNI in Hepatocellular Carcinoma

“…Hypoalbuminemia is a common complication of many diseases, such as various types of malignant tumors and chronic inflammatory disease. Albumin level can also be used as one of the effective prognostic predictors of various tumor and nontumor diseases [37][38][39][40][41]. Low serum albumin level is related to the poor prognosis of tumor diseases, and the specific mechanism is unclear.…”

Elevated serum α-hydroxybutyrate dehydrogenase is an independent risk factor for survival outcomes in UTUC patients after radical nephroureterectomy

“…For the whole group, the level of hemoglobin, which represented the basic physical condition, was also an independent risk factor for OS and CSS, but albumin failed. Hypoalbuminemia was previously proved to be strongly associated with cancer patients' worsened OS and PFS, but the clinical practice of the single factor was limited because it could be easily affected by liver function, uid volume and systemic in ammatory [21][22][23] . It might be the reason of the above phenomenon.…”